G361人黑色素瘤細(xì)胞、G36 返回列表頁(yè)

G361 人黑色素瘤細(xì)胞
Catalogue No.: C634
Product Format: a T25 flask
Culture Properties：貼壁
Complete Growth Medium: 89%H-DMEM+10%FBS+1%雙抗
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Application: Cells and cancer research
NOTE: FOR RESEARCH USE ONLY.

Components

Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne disease with a high fatality rate. The clinical diagnosis criteria mainly rely on white blood cell (WBC) and platelet (PLT), which, however, are of limited usage in identifying atypical SFTS. A multicenter study was performed in two hospitals from 2011 to 2023. SFTS patients were categorized as atypical or typical based on the clinical diagnosis criteria. Clinical progress and outcomes were compared between the two groups. A total of 2876 laboratory-confirmed SFTS patients were included in this study, 90.54% (2604/2876) of whom exhibited both thrombocytopenia and leukopenia and were defined as typical SFTS patients, while 9.46% (272/2876) were defined as atypical SFTS patients. Patients with typical SFTS were more likely to develop complications (adjusted odds ratio [OR]?=?2.09, 95% confidence interval [CI]:1.48-2.92, p?

the last decade. Currently, most of the agents used to modify the tumor microenvironment are small molecules or antibodies. Small molecules exhibit low abdgnity and specificity towards the target and antibodies have shortcominkl such as poor tissue penetration and high production cost. Peptides may overcome these drawbacks and therefore are promising materials for immunomodulating agents. Here we systematically summarize the